anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formula I (X is halogen) or acid addition salt thereof. EXAMPLE:8-Bromocordycepin. USE:A biochemical reagent, medicine, e.g. carcinostatic agent, etc., and intermediate for production thereof. PREPARATION:Cordycepin expressed by formula II is reacted with a halogenating agent, e.g. bromine solution, N-bromosuccinimide, N- bromoacetamide, etc., preferably in a buffer solution at pH 3.5-4.5 and 20-50 deg.C for 2-4hr to afford the aimed compound expressed by formula I. The starting raw material expressed by formula II can be produced by reacting adenosine with 2-acetoxy-isobutyryl chloride, then reacting the resultant product with sodium methylate and reducing the obtained 9-(2,3-anhydro-beta-D-ribofuranosyl) adenine with a super hydride.
A thin chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A thin chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both. A treated thin chitosan material can be utilized to control bleeding and assist in treatment and healing during a surgical procedure, including laparoscopic partial nephrectomy.
Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) is a pleiotropic peptide known to promote many beneficial processes following neural damage and cell death after stroke. Despite PACAP's known neurotrophic and anti-inflammatory properties, it has not realized its translational potential due to a poor pharmacokinetic profile (non-linear PK/PD), and limited Blood-Brain Barrier Penetration (BBB) permeability. We have previously shown that glycosylation of PACAP increases stability and enhances BBB penetration. In addition, our prior studies showed reduced neuronal cell death and neuroinflammation in models of Parkinson's disease and Traumatic Brain Injury (TBI). In this study we show that a PACAP(1-27) glucoside retains the known neurotrophic activity of native PACAP(1-27)in vitro and a 5-day daily treatment regimen (100 nM) leads to neurite-like extensions in PC12 cells. In addition, we show that intraperitoneal injection of a PACAP(1-27) lactoside (10 mg/kg) with improved BBB-penetration, given 1-hour after reperfusion in a Transient Middle Cerebral Artery Occlusion (tMCAO) mouse model, reduces the infarct size after the ischemic injury in males significantly by ∼ 36 %, and the data suggest a dose-dependency. In conclusion, our data support further development of PACAP glycopeptides as promising novel drug candidates for the treatment of stroke, an area with an urgent clinical need.
This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (<2 cm) low-risk papillary thyroid cancer (PTC) who were offered the choice of active surveillance (AS) or surgery (Clinicaltrials.gov NCT03271892). Participants completed a questionnaire one year after their treatment decision. The primary intention-to-treat analysis compared the mean decision regret scale total score between patients who chose AS or surgery. A secondary analysis examined one-year decision regret score according to treatment status. Secondary outcomes included quality of life, mood, fear of disease progression, and body image perception. We adjusted for age, sex, and follow-up duration in linear regression analyses. Results: The overall questionnaire response rate was 95.5% (191/200). The initial treatment choices of respondents were AS 79.1% (151/191) and surgery 20.9% (40/191). The mean age was 53 years (standard deviation [SD] 15 years) and 77% (147/191) were females. In the AS group, 7.3% (11/151) of patients crossed over to definitive treatment (two for disease progression) before the time of questionnaire completion. The mean level of decision regret did not differ significantly between patients who chose AS (mean 22.4, SD 13.9) or surgery (mean 20.9, SD 12.2) in crude (p = 0.730) or adjusted (p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3-18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS (p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.
Vaccination has significantly reduced the incidence of invasive infections caused by several bacterial pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. However, no vaccines are available for many other invasive pathogens. A major hurdle in vaccine development is the lack of functional markers to quantify vaccine immunity in eliminating pathogens during the process of infection. Based on our recent discovery of the liver as the major organ of vaccine-induced clearance of blood-borne virulent bacteria, we here describe a new vaccine evaluation system that quantitatively characterizes the key features of effective vaccines in shuffling virulent bacteria from the blood circulation to the liver resident macrophage Kupffer cells (KCs) and sinusoidal endothelial cells (LSECs) in mouse septic infection model. This system consists of three related correlates or assays: pathogen clearance from the bloodstream, pathogen trapping in the liver, and pathogen capture by KCs/LSECs. These readouts were consistently associated with the serotype-specific immunoprotection levels of the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) against lethal infection of S. pneumoniae, a major invasive Gram-positive pathogen of community-acquired infections in humans. Furthermore, the reliability and sensitivity of these correlates in reflecting vaccine efficacy were verified with whole cell vaccines of Klebsiella pneumoniae and Escherichia coli, two major Gram-negative pathogens in hospital-acquired invasive infections. This system may be used as effective readouts to evaluate the immunoprotective potential of vaccine candidates in the preclinical phase by filling the current technical gap in vaccine evaluation between the conventional in vitro approaches (e.g. antibody production and pathogen neutralization/opsonophagocytosis) and survival of immunized animals.
Children aged 3 to 8 years who had had their tonsil adenoidectomy were collected. Propofol 3mg/kg, remifentanil 3-5ug /kg and atropine 0.01mg/kg were used for intravenous induction intubation. Sevoflurane was used for intraoperative anesthesia, propartamol 30mg/kg and hydromorphone 5-10ug /kg were used for postoperative analgesia.When sevoflurane was shut down at the end of the operation, oxygen flow was increased to more than 7L/min, and extubation was prepared for spontaneous respiration recovery, propofol was given a small amount of 1\~2mg/kg multiple times without inhibition of spontaneous respiration.
Screening - The study will be advertised through various public media sources (social media, posted flyers, Purdue Today) and a verbal conversation. Participants responding to the advertisements will be scheduled for a screening visit. This meeting will begin with a full description of the study, and investigators will secure informed written consent. Participants will complete questionnaires eliciting demographic (age, biological sex, BMI, fat%), dietary (eating traits), and health (acute and chronic disease history) information. Height and weight will be measured. For those choosing to enroll, investigators will obtain baseline measurements to confirm eligibility. Individuals qualified and volunteering to participate in the trial will complete multiple questionnaires about eating habits ( Meal pattern questionnaire, Power of food scale, 0 Study Materials - Appetite Training Material.pdf 0 Study Materials - ASA24 instruction .pdf 0 Eating Trait questionnaires.pdf 0 Study Materials - Appetite Lexicon Quiz.docx 0 Hourly Appetite and Thirst Ratings.pdf 0 Study Timeline.pdf Emotional eating scale, Eating inventory, Food craving inventory, Adult eating behavior scales, Self-regulation of eating behavior questionnaire, Barrot Impulsiveness scale). Participants will also learn how to record their energy intake through the ASA-24 system. Then, participants will get training on the lexicon of appetite sensations with a video tutorial, followed by an online quiz to confirm their understanding of the concepts. At least 90% of correct responses are required to pass the appetite lexicon training. Failure to satisfactorily convey an understanding of the concepts will result in an offer to repeat the training two more times or be rejected from the study. Study Procedure - Enrolled participants will have a virtual meeting with a researcher (E. Cheon) once a week through Zoom to remind participants about the necessity and method for recording of appetite/thirst ratings, dietary recalls, and physical activity to be completed during three days (2 non-consecutive weekdays and

1 weekend day). Participants will be asked to report to the laboratory for instruction on recording appetitive sensations (hunger, fullness, thirst), food intake, physical activity at baseline (week1), week 9, and 17 on 3 days (2 non-consecutive weekdays and 1 weekend day). Ratings of hunger, fullness, and thirst will be recorded on their cell phones/computers via a web-based Qualtrics survey every waking hour for 3 days. All entries are time and date stamped to ensure the ratings are made at the intended times. Participants will be provided hourly alarms to ensure regular recording.

Concurrently, participants will keep a diet record with an ASA-24 system and free-living energy expenditure will be measured using a physical activity tracking application on the same days of appetite ratings.
The invention discloses intramuscular injection solution for enhancing immunity. Pidotimod and sodium hydroxide or potassium hydroxide or arginine and the like are reacted in water or ethanol or mixed solution of water and ethanol so as to generate pidotimod sodium salt, potassium salt or arginine salt, and then the injection solution is prepared. The intramuscular injection solution is characterized in that: the pidotimod which is an active component in the injection solution exists in the form of the pidotimod sodium salt or the potassium salt or the arginine salt, and the pH value of the solution is within 4.0 to 6.0. The optimal range of the pidotimod or the pidotimod sodium salt or the potassium salt or the arginine salt in every 1ml injection is within 50 to 250mg. The preferential specification is 2ml: 0.2g or 3ml: 0.2g (according to the pidotimod). The injection solution is used for treating the following diseases: (1) repeated upper and lower respiratory tract infection (pharyngitis, trachitis, bronchitis and amygdalitis); (2) repeated infection of otorhinolaryngology (rhinitis, nasosinusitis and otitis); (3) infection of a urinary system; (4) infection of gynaecology; (5) clinical patients with poor cellular immune function after chemotherapy; (6) specific and non-specific immunodeficiency diseases such as cancer and the like. The injection solution is used for reducing the acute disease attacking number of times, shortening course of the disease and relieving the attacking degree. Moreover, the injection solution can also be used for adjuvant therapy of antibiotics when in acute infection.
The existence of the cerebrospinal fluid and the intracranial pressure contribute the susceptibility of the CNS to injuries. A lymph-like composition and method for treating brain and spinal cord injuries are provided. The lymph-like composition comprises Polypeptides, Insulin, Mg +  and ATP in an artificial cerebrospinal fluid. The method includes: a). Administering an agent to reduce the CSF production, b). Withdrawing a volume of cerebrospinal fluid, and c). Repeatedly injecting and withdrawing an effective amount of lymph-like composition through the subarachnoid space to wash the central nervous system tissue where protection is needed, and finally removing an effective amount of lymph-like composition to maintain a lower the intracranial pressure.
The proposed intervention is a 10-week app-based program, SafeSpace Sexual Health. SafeSpace Sexual Health will be implemented using a secure, anonymous mobile app that uses authentic stories to engage young people with sexual health information and resources. The program addresses healthy relationships, anatomy and physiology, identity, adolescent development, STIs/HIV, pregnancy and reproduction, decision-making, personal safety, communication, and accessing healthcare. Each lesson includes a story written by youth with lived experience, two to three key facts developed by sexual health experts, a reflection prompt, and two to three reputable resources.
PROBLEM TO BE SOLVED: To provide a use of gelsolin to treat infections and sepsis, and to provide a use of gelsolin to monitor and evaluate treatments of infections.SOLUTION: The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression. This invention is based on the surprising discovery that gelsolin treats infections and protects against the toxic manifestations of infections. It is found that mice injected with gelsolin subsequent to the exposure to an infectious agent unexpectedly survived better than mice given saline. Thus, the invention involves in one aspect, the administration of gelsolin to a subject to treat an infection. The invention also relates to methods for using gelsolin to treat the biological effects of infections.
Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
BACKGROUND: As acute myocardial infarction (AMI) prevalence is increasing because of lifestyle changes, the incidence of atypical symptoms in acute coronary syndrome (ACS) is rising and making misdiagnosing of this fatal event more probable. To better approach the patients with atypical symptoms, we tend to present a rare case of AMI with wrist pain.
CASE REPORT: A 41-year-old man presented to the emergency room (ER) with severe both-hand wrist pain and mild epigastric pain. His electrocardiogram (ECG) showed anterior ST-elevation myocardial infarction (MI) with an ejection fraction of 35-40%. His angiography showed severe left anterior descending artery (LAD), and first obtuse marginal artery (OM1) artery stenosis. He underwent Primary percutaneous coronary intervention (PCI). The patient recovered without serious complications and was discharged the day after PCI.
DISCUSSION: In this rare case of AMI with wrist pain, it is important to know that atypical symptoms can be present at various levels of symptoms, which prevents future misdiagnosis.
Internal herniation (IH) is a common problem after laparoscopic Roux-en-Y gastric bypass surgery (RYGB). Routine closure of the mesenteric defects (MDs) reduces the risk of IH. Only very few articles report on risk factors for IH or describe detailed closing techniques. There is no consensus yet on the best closing method. The objective of this study is to determine the optimal stapling method for closure of MDs after RYGB. All performed RYGB procedures in our high-volume bariatric institute were included. Quality of the closure was scored in the categories poor, sub-optimal, and optimal, to see if the quality of the closure would predict the chance of reopening of the MDs and, therefore, the chance of IH. During any type of laparoscopy in the follow-up of the patient, the conditions of the MDs were stated, for example during diagnostic laparoscopy in symptomatic patients suspicious for IH or during laparoscopic cholecystectomy. Technically well-executed closure of Petersen's space (PS) with two rows of staples had a greater chance of still being closed upon re-inspection compared to closure with one row (odds ratio = 8.1; 95% confidence interval [1.2-53.2], p = 0.029). Optimal closure of the MD at the jejuno-jejunostomy (JJ-space, JJS) resulted in more closed JJSs upon re-inspection compared to sub-optimal closure (odds ratio = 3.6 [CI 95% 0.8-16.1], p = 0.099). Non-optimally closed MDs had higher reopening rates and, therefore, pose an additional risk for IH. Our classification provides a quality assessment of MD closure during RYGB and gives insight into how to optimize surgical technique.
A pre-analytical sample management system configured to process a sample and manage one or more sample containers, the system comprising an interactive display for input and/or output operations 1, a sample container loader 2, a sample container registration unit 3, a sample mixer unit 5, a centrifugation unit 6, a sampling sorting unit 7, a sample storage unit 8 and a data processing unit 4. The system is a used for sample management, tracking and processing in a medical environment such as a hospital or doctor’s surgery. The display unit may be used to input data, verify patient or practitioner ID or give operator guidance. The container loader is a mechanical container displacement device such as a robotic component. The registration unit may be an optical detection unit, such as a camera or spectroscope, for identifying a sample container. The sorting unit automatically sorts and separates sample containers based upon factors such as container ID, cap colour, shape, storage requirements, and intermediate and final destinations. The storage unit retains the containers and may be a temperature-controlled environment. The containers may be transported for subsequent analysis, with the system connected to a pneumatic tube transport system. Optionally, the system comprises a container labelling unit and/or an analytical unit.
International recommendations call for exploratory paracentesis to be performed on admission in all cirrhotic patients presenting with clinical ascites. Based on data from a study published in 1990, the diagnosis of spontaneous bacterial infection (SBP) is defined by the presence of neutrophils (PNN) ≥ 250/mm3 in ascites fluid, irrespective of the bacteriological culture result . Although culture of ascites fluid is negative in 40-60% of confirmed cases of ISLA, and it takes 2-5 days to obtain a result, it remains essential to best adapt antibiotic therapy. Empirical antibiotic therapy is started as soon as SBP is diagnosed. Response to antibiotic therapy is defined as a reduction of more than 25% in the number of PNN in ascites sampled 48 hours after initiation of treatment. However, the landmark study by Akriviadis et al showed that the mean number of PNN fell significantly as early as 24 hours after the start of treatment, with a drop in PNN as early as the 6th hour. In the absence of a response to treatment, antibiotic therapy should be modified on the basis of culture results if positive, or empirically in the absence of bacteriological documentation. A recent study showed that a reduction in the number of PNN in ascites fluid after effective empirical antibiotic therapy was significantly associated with improved survival. Thus, waiting 48 hours to perform a follow-up paracentesis could delay the adjustment of effective antibiotic therapy in the event of initial non-response, and thus worsen the prognosis of SBP.
PCT No. PCT/US91/01142 Sec. 371 Date Aug. 28, 1992 Sec. 102(e) Date Aug. 28, 1992 PCT Filed Feb. 21, 1991 PCT Pub. No. WO91/13088 PCT Pub. Date Sep. 5, 1991.This invention relates to antiviral peptide compounds and to methods of inhibiting infection of human cells by viruses. This invention pertains more specifically to peptides that are chemically blocked at the amino- and carboxy-termini. In particular the invention relates to peptides comprised of prolylalanine or prolylphenylalanine compounds that have antiviral activity. The invention is specifically directed to methods for preventing infection of human cells in vivo and in vitro with the human immunodeficiency virus HIV-1 and methods for treating human infected with this and other viruses. The invention also relates to the diagnostic and therapeutic use of these antiviral peptide compounds.
Nanofiber beauty mask relates to the fabric and nanofibers fields. Skin cells lose their freshness through aging and because of the dryness of the weather or environments, skin dries or hurts. The purpose of this invention is to use nanofiber technology in producing beauty masks because they cure the occurred facial problems, protect the skin from dryness and injuries, and keep it fresh and glowing. The produced beauty mask with nanofiber is combined of three layers, the first layer is a non-woven fabric, and polyurethane adhesive is used in the middle layer on which the nanofiber forms over it. The third layer (in contact with the skin) contains PVA nanofiber including aloe vera and chitosan, with a diameter between 100 to 600 nanometers. Nanofibers are produced with an electrospinning process, and due to their fineness, they expand wider over the skin and contact the cells. Nanofiber beauty masks have regular
The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
Vitamin B12 values are obtained from an impure solution containing the same, e.g. from impure liver extracts or bacterial culture media, by treating said solution at a pH of at least 7 with a cyanide salt, e.g. an alkali metal cyanide, acidifying the solution, removing excess cyanide, treating the aqueous solution in the presence of a neutral inorganic salt, e.g. ammonium or sodium sulphate, with an alcoholic solvent, e.g. butanol, extracting the organic solvent solution with water, and treating the extract with a normally liquid, aliphatic, monocarboxylic acid containing between 4 and 14 carbon atoms.  As monocarboxylic acids there may be used: n-caproic acid, 2-ethylhexoic acid, 2-ethylbutyric acid, capric acid, cyclohexylacetic acid, cyclohexylbutyric acid, n-caprylic acid and lauric acid.  Said acid may be first dissolved in a water-immiscible alcohol.  Prior to the cyanide treatment and carboxylic acid extraction the vitamin B12 values may be purified by adsorbtion on activated charcoal and elution therefrom with an alcohol-water mixture.  Reference has been directed by the Comptroller to Specification 681,503.